Welcome to our dedicated page for Monte Rosa Therapeutics SEC filings (Ticker: GLUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company developing molecular glue degrader (MGD) medicines, Monte Rosa uses SEC reports to describe its clinical programs, collaborations, and financial condition.
Among the most informative documents for GLUE are current reports on Form 8-K, which the company uses to announce material events such as interim clinical data, financial results, and collaboration updates. For example, Monte Rosa has furnished 8-Ks summarizing positive interim Phase 1/2 data for MRT-2359 in metastatic castration-resistant prostate cancer and reporting quarterly financial results and business updates, including progress on MRT-8102, MRT-6160, and its partnerships with Novartis and Roche.
Investors can also reference Monte Rosa’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which the company cites in its forward-looking statements as sources of detailed risk factors and operational information. These periodic filings typically include descriptions of the QuEEN™ discovery engine, the status of key programs such as MRT-8102, MRT-2359, and MRT-6160, and the structure of collaboration and license agreements.
On Stock Titan, GLUE filings are updated in near real time as they appear in the SEC’s EDGAR system. AI-powered tools help summarize lengthy documents, highlight key sections on clinical development, collaboration revenue, and cash runway, and make it easier to locate items on topics such as interim trial results, planned Phase 2 studies, or changes in capital structure. Users can quickly review Form 8-K disclosures about material events alongside the underlying press releases and presentations referenced in those filings.
Morgan Stanley Smith Barney LLC Executive Financial Services filed a Form 144 disclosing the proposed sale of 536 common shares by means of a stock option exercise on 03/02/2026. The filing lists cash proceeds as the method of settlement.
The excerpt also reports recent open-market sales by Edmund Dunn of 25,164 shares for $455,506.15 on 02/27/2026 and 1,039 shares for $15,762.65 on 01/05/2026.
Issuer files a Form 144 reporting proposed sale of 25,164 common shares. The filing lists the transaction type as a Stock Option Exercise with a sale date of 02/27/2026. It also shows prior shares sold of 1,039 on 01/05/2026 for $15,762.65.
Monte Rosa Therapeutics Chief Medical Officer Filip Janku reported an open-market sale of company stock. On February 23, 2026, he sold 9,189 shares of common stock at an average price of $19.4973 per share and now directly owns 65,837 shares.
GLUE insider notice to sell common stock. Filip Janku filed a Form 144 reporting a proposed sale of 3,155 common shares on 01/05/2026 with an aggregate value of $47,863.58.
The filing lists prior ESPP-related share lots with dates and share counts (12/29/2023: 1,282; 12/30/2022: 1,820; 06/30/2023: 2,150; 06/28/2024: 3,937). These rows describe securities and dates as shown in the excerpt.
Monte Rosa Therapeutics, Inc. received an updated ownership report from a group of investment entities associated with Biotechnology Value Fund and Mark N. Lampert. As of December 31, 2025, these Reporting Persons may be deemed to beneficially own a total of 3,835,886 shares of Monte Rosa common stock, representing approximately 5.9% of the 65,117,761 shares outstanding as of October 31, 2025. Individual funds hold portions of this stake, including 2,050,405 shares at Biotechnology Value Fund, 1,496,859 shares at Biotechnology Value Fund II, and 232,097 shares at Biotechnology Value Trading Fund OS. The filing states the shares were not acquired and are not held for the purpose of changing or influencing control of the company.
Baker Bros. Advisors and affiliates report a 6.7% ownership stake in Monte Rosa Therapeutics, Inc. (GLUE) common stock. They beneficially own 4,345,736 shares based on 65,117,761 shares outstanding as of October 31, 2025, as cited from the company’s Form 10-Q.
The stake is held through two investment funds: 667, L.P. with 343,372 shares (0.5% of the class) and Baker Brothers Life Sciences, L.P. with 4,002,364 shares (6.2% of the class). Baker Bros. Advisors LP has discretion over investment and voting decisions, and the filing is certified as being made in the ordinary course of business without intent to influence control.
Monte Rosa Therapeutics, Inc. has filed an automatic shelf registration and a related at-the-market program to sell up to $100,000,000 of common stock through Jefferies on a commission of 3% of gross proceeds. Shares will be sold from time to time at market prices.
The company plans to use any net proceeds for general corporate purposes, including research and clinical development of its molecular glue degrader pipeline, working capital, capital expenditures and office expansion. Monte Rosa remains an emerging growth and smaller reporting company with lead programs in immunology, inflammation and oncology.
Monte Rosa Therapeutics, Inc. reported that Edmund Dunn plans to retire from his role as Senior Vice President, Corporate Controller and Principal Accounting Officer, effective April 3, 2026. The company states that his retirement is not due to any disagreement over operations, policies, or practices and that he will not receive severance payments or benefits tied to his departure.
Effective the same date, Matthew Bowen, age 37, will become Corporate Controller and Principal Accounting Officer. Bowen joined Monte Rosa’s finance department after its June 2021 initial public offering and has held roles of increasing responsibility, most recently as Director, Finance. He previously spent seven years in Ernst & Young LLP’s audit and assurance practice, primarily auditing large public companies. The filing notes there are no special arrangements, family relationships, or related-party transactions connected to his promotion.
Monte Rosa Therapeutics, Inc. has a large shareholder group reporting passive ownership of its common stock. Dimension Capital I, L.P. directly holds 5,663,265 shares of common stock, and together with affiliated entities and individuals Adam Goulburn, Zavain Dar, and Nan Li, this position represents 8.7% of the company’s outstanding shares.
The ownership percentage is calculated using 65,117,761 shares of common stock outstanding as of October 31, 2025, as disclosed in Monte Rosa’s Form 10-Q. The reporting group certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of Monte Rosa, indicating a passive investment stance rather than an activist position.
Monte Rosa Therapeutics, Inc. entered into an underwriting agreement for an underwritten public offering of 11,125,000 shares of common stock at $24.00 per share and pre-funded warrants to purchase 1,375,000 shares at $23.9999 per warrant, with each warrant having a $0.0001 exercise price. The company also granted underwriters a 30-day option to buy up to 1,875,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions.
Monte Rosa estimates net proceeds of approximately $281.6 million from this offering, excluding any proceeds from the underwriters’ option. It plans to use the cash, together with existing balances, to advance MRT-8102 in chronic inflammatory diseases including atherosclerotic cardiovascular disease, further develop its QuEENTM platform across immunology, inflammation and oncology targets, and for working capital and general corporate purposes. The offering is expected to close on or about January 12, 2026, and the company expects its cash and cash equivalents to fund planned operations and capital expenditures into 2029.